These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

573 related articles for article (PubMed ID: 12814173)

  • 1. Long-term follow up of patients with clinically isolated syndromes, relapsing-remitting and secondary progressive multiple sclerosis.
    Eriksson M; Andersen O; Runmarker B
    Mult Scler; 2003 Jun; 9(3):260-74. PubMed ID: 12814173
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Natural history of multiple sclerosis: a unifying concept.
    Confavreux C; Vukusic S
    Brain; 2006 Mar; 129(Pt 3):606-16. PubMed ID: 16415308
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A representative cohort of patients with non-progressive multiple sclerosis at the age of normal life expectancy.
    Skoog B; Runmarker B; Winblad S; Ekholm S; Andersen O
    Brain; 2012 Mar; 135(Pt 3):900-11. PubMed ID: 22366800
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Poor early relapse recovery affects onset of progressive disease course in multiple sclerosis.
    Novotna M; Paz Soldán MM; Abou Zeid N; Kale N; Tutuncu M; Crusan DJ; Atkinson EJ; Siva A; Keegan BM; Pirko I; Pittock SJ; Lucchinetti CF; Noseworthy JH; Weinshenker BG; Rodriguez M; Kantarci OH
    Neurology; 2015 Aug; 85(8):722-9. PubMed ID: 26208962
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ten-year prognosis in multiple sclerosis: a better outcome in relapsing-remitting patients but not in primary progressive patients.
    Kerbrat A; Hamonic S; Leray E; Tron I; Edan G; Yaouanq J;
    Eur J Neurol; 2015 Mar; 22(3):507-e35. PubMed ID: 25515927
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relapses and progression of disability in multiple sclerosis.
    Confavreux C; Vukusic S; Moreau T; Adeleine P
    N Engl J Med; 2000 Nov; 343(20):1430-8. PubMed ID: 11078767
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term disability progression of pediatric-onset multiple sclerosis.
    McKay KA; Hillert J; Manouchehrinia A
    Neurology; 2019 Jun; 92(24):e2764-e2773. PubMed ID: 31092624
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of genetic susceptibility variants in predicting clinical course in multiple sclerosis: a cohort study.
    Pan G; Simpson S; van der Mei I; Charlesworth JC; Lucas R; Ponsonby AL; Zhou Y; Wu F; Taylor BV
    J Neurol Neurosurg Psychiatry; 2016 Nov; 87(11):1204-1211. PubMed ID: 27559181
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prospective study of multiple sclerosis with early onset.
    Ghezzi A; Pozzilli C; Liguori M; Marrosu MG; Milani N; Milanese C; Simone I; Zaffaroni M
    Mult Scler; 2002 Apr; 8(2):115-8. PubMed ID: 11990867
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early Clinical Features, Time to Secondary Progression, and Disability Milestones in Polish Multiple Sclerosis Patients.
    Rzepiński Ł; Zawadka-Kunikowska M; Maciejek Z; Newton JL; Zalewski P
    Medicina (Kaunas); 2019 May; 55(6):. PubMed ID: 31159275
    [No Abstract]   [Full Text] [Related]  

  • 11. Changes in the Risk of Reaching Multiple Sclerosis Disability Milestones In Recent Decades: A Nationwide Population-Based Cohort Study in Sweden.
    Beiki O; Frumento P; Bottai M; Manouchehrinia A; Hillert J
    JAMA Neurol; 2019 Jun; 76(6):665-671. PubMed ID: 30882868
    [TBL] [Abstract][Full Text] [Related]  

  • 12. T2 lesions and rate of progression of disability in multiple sclerosis.
    Mostert JP; Koch MW; Steen C; Heersema DJ; De Groot JC; De Keyser J
    Eur J Neurol; 2010 Dec; 17(12):1471-5. PubMed ID: 20500805
    [TBL] [Abstract][Full Text] [Related]  

  • 13. How effective are disease-modifying drugs in delaying progression in relapsing-onset MS?
    Brown MG; Kirby S; Skedgel C; Fisk JD; Murray TJ; Bhan V; Sketris IS
    Neurology; 2007 Oct; 69(15):1498-507. PubMed ID: 17699802
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Defining reliable disability outcomes in multiple sclerosis.
    Kalincik T; Cutter G; Spelman T; Jokubaitis V; Havrdova E; Horakova D; Trojano M; Izquierdo G; Girard M; Duquette P; Prat A; Lugaresi A; Grand'Maison F; Grammond P; Hupperts R; Oreja-Guevara C; Boz C; Pucci E; Bergamaschi R; Lechner-Scott J; Alroughani R; Van Pesch V; Iuliano G; Fernandez-Bolaños R; Ramo C; Terzi M; Slee M; Spitaleri D; Verheul F; Cristiano E; Sánchez-Menoyo JL; Fiol M; Gray O; Cabrera-Gomez JA; Barnett M; Butzkueven H
    Brain; 2015 Nov; 138(Pt 11):3287-98. PubMed ID: 26359291
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sunlight exposure and sun sensitivity associated with disability progression in multiple sclerosis.
    D'hooghe MB; Haentjens P; Nagels G; Garmyn M; De Keyser J
    Mult Scler; 2012 Apr; 18(4):451-9. PubMed ID: 21952096
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Brain lesion location and clinical status 20 years after a diagnosis of clinically isolated syndrome suggestive of multiple sclerosis.
    Dalton CM; Bodini B; Samson RS; Battaglini M; Fisniku LK; Thompson AJ; Ciccarelli O; Miller DH; Chard DT
    Mult Scler; 2012 Mar; 18(3):322-8. PubMed ID: 21878451
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multiple sclerosis: clinical characteristics and disability progression in Moroccan children.
    Ait Ben Haddou E; Alhyan M; Aasfara J; Regragui W; Ibrahimi A; Razine R; Abouqal R; Benomar A; Yahyaoui M
    J Neurol Sci; 2014 Nov; 346(1-2):128-32. PubMed ID: 25216553
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Natural history of secondary-progressive multiple sclerosis.
    Tremlett H; Yinshan Zhao ; Devonshire V
    Mult Scler; 2008 Apr; 14(3):314-24. PubMed ID: 18208898
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Determinants of disability in multiple sclerosis at various disease stages: a multiparametric magnetic resonance study.
    Pulizzi A; Rovaris M; Judica E; Sormani MP; Martinelli V; Comi G; Filippi M
    Arch Neurol; 2007 Aug; 64(8):1163-8. PubMed ID: 17698707
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cerebrospinal fluid oligoclonal bands and progression of disability in multiple sclerosis.
    Koch M; Heersema D; Mostert J; Teelken A; De Keyser J
    Eur J Neurol; 2007 Jul; 14(7):797-800. PubMed ID: 17594338
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.